Abstract
Psychiatric hospitals in Austria have about 10000 beds for acute and chronic patients. We estimate that schizophrenic patients are responsible for about 20% of all acute hospital admissions, while the percentage of schizophrenics in long-stay units probably exceeds 30%. Twenty-nine neuroleptics of the various chemical classes are currently registered and marketed in Austria. Four of these (haloperidol, fluphenazine, flupenthixol and clopenthixol) are available in long-acting injectible depot preparations; one (penfluridol) is a long-acting oral antipsychotic.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Fleischhacker, W.W., Meise, U. (1991). Austria: The Current Status of Maintenance Treatment in Schizophrenia. In: Kissling, W. (eds) Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-86922-8_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-86922-8_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-53985-8
Online ISBN: 978-3-642-86922-8
eBook Packages: Springer Book Archive